Blueprint Medicines Corporation (BPMC)
Jul 18, 2025 - BPMC was delisted (reason: acquired by SNY)
129.46
0.00 (0.00%)
Inactive · Last trade price on Jul 17, 2025

Company Description

Blueprint Medicines Corporation operates as a global biopharmaceutical company that develops medicines for genomically defined cancers, blood disorders, and allergy/inflammation in the United States and internationally.

The company develops AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.

It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations.

In addition, the company develops BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers.

Blueprint Medicines Corporation was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011.

The company was incorporated in 2008 and is based in Cambridge, Massachusetts. As of July 18, 2025, Blueprint Medicines Corporation operates as a subsidiary of Sanofi.

Blueprint Medicines Corporation
Blueprint Medicines logo
CountryUnited States
Founded2008
IPO DateApr 30, 2015
IndustryBiotechnology
SectorHealthcare
Employees649
CEOKathryn Haviland

Contact Details

Address:
45 Sidney Street
Cambridge, Delaware 02139
United States
Phone(617) 374-7580
Websiteblueprintmedicines.com

Stock Details

Ticker SymbolBPMC
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001597264
CUSIP Number09627Y109
ISIN NumberUS09627Y1091
SIC Code2836

Key Executives

NamePosition
Kathryn Haviland M.B.A.President, Chief Executive Officer and Director
Alexis A. Borisy A.M.Co-Founder and Director
Michael Landsittel CPAChief Financial Officer
Christina Rossi M.B.A.Chief Operating Officer
Dr. Percy H. Carter M.B.A., Ph.D.Chief Scientific Officer
Dr. Fouad Namouni M.D.President of Research and Development
Ariel HurleySenior Vice President of Finance and Principal Accounting Officer
Jenna CohenSenior Director and Head of Investor Relations
Tracey L. McCain Esq.Executive Vice President, Chief Legal and Compliance Officer and Secretary
Debra Durso-BumpusChief People Officer

Latest SEC Filings

DateTypeTitle
Jul 18, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Jul 18, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Jul 18, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Jul 18, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Jul 18, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Jul 18, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Jul 18, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Jul 18, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Jul 18, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Jul 18, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments